{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:35:48Z","timestamp":1785825348354,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03624-x","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:10Z","timestamp":1738061950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study"],"prefix":"10.1186","volume":"23","author":[{"given":"Bin","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"16","key":"3624_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3624_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"3624_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"3","key":"3624_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3624_CR5","doi-asserted-by":"crossref","unstructured":"Yeh JH, Yeh YS, Tsai HL et al. Neoadjuvant chemoradiotherapy for locally advanced gastric cancer: where are we at? cancers (Basel). 2022;14(12).","DOI":"10.3390\/cancers14123026"},{"issue":"17","key":"3624_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.21037\/atm-20-3509","volume":"8","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Almhanna K. Locoregional gastric cancer: a narrative review of multidisciplinary management. Ann Transl Med. 2020;8(17):1108.","journal-title":"Ann Transl Med"},{"issue":"1","key":"3624_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, et al. The chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2024;44(1):127\u201372.","journal-title":"Cancer Commun (Lond)"},{"key":"3624_CR8","doi-asserted-by":"crossref","unstructured":"Koerner AS, Moy RH, Ryeom SW, Yoon SS. The present and future of neoadjuvant and adjuvant therapy for locally advanced gastric cancer. Cancers (Basel). 2023;15(16).","DOI":"10.3390\/cancers15164114"},{"issue":"1","key":"3624_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3624_CR10","first-page":"147","volume":"6","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med. 2020;6(3):147\u201357.","journal-title":"Chronic Dis Transl Med"},{"issue":"1","key":"3624_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5230\/jgc.2023.23.e12","volume":"23","author":"X Tong","year":"2023","unstructured":"Tong X, Zhi P, Lin S. Neoadjuvant chemotherapy in asian patients with locally advanced gastric cancer. J Gastric Cancer. 2023;23(1):182\u201393.","journal-title":"J Gastric Cancer"},{"key":"3624_CR12","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.","journal-title":"Cancer Treat Rev"},{"key":"3624_CR13","doi-asserted-by":"publisher","first-page":"1148131","DOI":"10.3389\/fonc.2023.1148131","volume":"13","author":"D Xu","year":"2023","unstructured":"Xu D, Luo Y, Wang P, et al. Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer. Front Oncol. 2023;13:1148131.","journal-title":"Front Oncol"},{"issue":"6","key":"3624_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22(6):476\u201395.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3624_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3174\/ajnr.A1987","volume":"31","author":"SK Mukherji","year":"2010","unstructured":"Mukherji SK. Bevacizumab (Avastin). AJNR Am J Neuroradiol. 2010;31(2):235\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"3624_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/cncr.29800","volume":"122","author":"W Ou","year":"2016","unstructured":"Ou W, Li N, Wang SY, et al. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). Cancer. 2016;122(5):740\u20137.","journal-title":"Cancer"},{"issue":"4","key":"3624_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.breast.2013.03.012","volume":"22","author":"M Clavarezza","year":"2013","unstructured":"Clavarezza M, Turazza M, Aitini E, et al. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Breast. 2013;22(4):470\u20135.","journal-title":"Breast"},{"key":"3624_CR18","doi-asserted-by":"publisher","first-page":"4227650","DOI":"10.1155\/2021\/4227650","volume":"2021","author":"J Song","year":"2021","unstructured":"Song J, Wang Y, Yu H, Zheng L, Cai X, Chen Y. Neoadjuvant chemotherapy plus bevacizumab combined with total mesorectal excision in treating locally advanced rectal cancer patients with braf mutation: clinical benefit and safety. Comput Math Methods Med. 2021;2021:4227650.","journal-title":"Comput Math Methods Med"},{"issue":"42","key":"3624_CR19","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1097\/MD.0000000000001489","volume":"94","author":"J Ma","year":"2015","unstructured":"Ma J, Yao S, Li XS, Kang HR, Yao FF, Du N. Neoadjuvant therapy of DOF regimen plus bevacizumab can increase surgical resection ratein locally advanced gastric cancer: a randomized, controlled study. Med (Baltim). 2015;94(42):e1489.","journal-title":"Med (Baltim)"},{"key":"3624_CR20","doi-asserted-by":"publisher","first-page":"842828","DOI":"10.3389\/fsurg.2022.842828","volume":"9","author":"D Yu","year":"2022","unstructured":"Yu D, Wang Z, He T, Yang L. Neoadjuvant bevacizumab plus docetaxel\/cisplatin\/capecitabine chemotherapy in locally advanced gastric cancer patients: a pilot study. Front Surg. 2022;9:842828.","journal-title":"Front Surg"},{"issue":"3","key":"3624_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","volume":"18","author":"D Cunningham","year":"2017","unstructured":"Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial. Lancet Oncol. 2017;18(3):357\u201370.","journal-title":"Lancet Oncol"},{"key":"3624_CR22","doi-asserted-by":"publisher","first-page":"4900037","DOI":"10.1155\/2022\/4900037","volume":"2022","author":"F Wei","year":"2022","unstructured":"Wei F. Clinical efficacy and adverse reactions of bevacizumab plus radiochemotherapy in the treatment of advanced gastric cancer. J Oncol. 2022;2022:4900037.","journal-title":"J Oncol"},{"issue":"1","key":"3624_CR23","first-page":"55","volume":"15","author":"YB Zheng","year":"2012","unstructured":"Zheng YB, Cao FY, Liu KJ, Gan HF, He XB, Tong SL. Value of normalization window of tumor vasculature in neoadjuvant chemotherapy for patients with unresectable gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15(1):55\u20138.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"30","key":"3624_CR24","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968\u201376.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3624_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747\u201395.","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"3624_CR26","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/cncr.29864","volume":"122","author":"D Meulendijks","year":"2016","unstructured":"Meulendijks D, de Groot JW, Los M, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer. 2016;122(9):1434\u201343.","journal-title":"Cancer"},{"key":"3624_CR27","first-page":"6189833","volume":"2022","author":"L Wang","year":"2022","unstructured":"Wang L, Li W, Liu YG, Zhang C, Gao WN, Gao LF. Clinical efficacy and safety of bevacizumab, apatinib, and recombinant human endothelial inhibitor in the treatment of advanced gastric cancer. J Oncol. 2022;2022:6189833.","journal-title":"J Oncol"},{"key":"3624_CR28","doi-asserted-by":"crossref","unstructured":"Nakayama I, Takahari D. The role of angiogenesis targeted therapies in metastatic advanced gastric cancer: a narrative review. J Clin Med. 2023;12(9).","DOI":"10.3390\/jcm12093226"},{"issue":"5","key":"3624_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00432-024-05714-5","volume":"150","author":"Y Kang","year":"2024","unstructured":"Kang Y, Li H, Liu Y, Li Z. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors. J Cancer Res Clin Oncol. 2024;150(5):221.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5706","key":"3624_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"issue":"Suppl 1","key":"3624_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1634\/theoncologist.9-suppl_1-36","volume":"9","author":"E Bergsland","year":"2004","unstructured":"Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 2004;9(Suppl 1):36\u201342.","journal-title":"Oncologist"},{"issue":"2","key":"3624_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3349\/ymj.2013.54.2.374","volume":"54","author":"JE Hwang","year":"2013","unstructured":"Hwang JE, Lee JH, Park MR, et al. Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. Yonsei Med J. 2013;54(2):374\u201380.","journal-title":"Yonsei Med J"},{"issue":"5777","key":"3624_CR33","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1126\/science.1125950","volume":"312","author":"RS Kerbel","year":"2006","unstructured":"Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006;312(5777):1171\u20135.","journal-title":"Science"},{"issue":"Supplement","key":"3624_CR34","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.4103\/ijc.IJC_1417_20","volume":"59","author":"S Patil","year":"2022","unstructured":"Patil S, Agarwal V, Drupad HS. Significance of emerging clinical oncology endpoints in support of overall survival. Indian J Cancer. 2022;59(Supplement):S106\u201318.","journal-title":"Indian J Cancer"},{"key":"3624_CR35","doi-asserted-by":"crossref","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182(152\u2009\u2013\u200960.","DOI":"10.1016\/j.pharmthera.2017.08.012"},{"issue":"1","key":"3624_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12672-022-00468-3","volume":"13","author":"S Hong","year":"2022","unstructured":"Hong S, Daniels B, van Leeuwen MT, Pearson SA, Vajdic CM. Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors. Discov Oncol. 2022;13(1):6.","journal-title":"Discov Oncol"},{"issue":"3","key":"3624_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1L426","volume":"43","author":"SM Gressett","year":"2009","unstructured":"Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490\u2013501.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"3624_CR38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2146\/ajhp080455","volume":"66","author":"SS Shord","year":"2009","unstructured":"Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66(11):999\u20131013.","journal-title":"Am J Health Syst Pharm"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03624-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03624-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03624-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:14Z","timestamp":1738061954000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03624-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3624"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03624-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee approved the study. The informed consents were obtained from patients or their family members.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}